Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

Reflux Oesophagitis Clinical Trial

Official title:

A Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of YF476, a Novel, Potent and Selective Gastrin/Cholecystokinin-B Antagonist, in Healthy Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01538784
• Other study ID #: 96-001
• Status: Completed
• Phase: Phase 1
• First received: February 15, 2012
• Last updated: February 20, 2012
• Start date: May 1996
• Est. completion date: June 1996

Study information

• Verified date: February 2012
• Source: Trio Medicines Ltd.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The objectives of the study were:

• To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers.

• To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.

Description:

YF476 is clearly a potent and selective gastrin/CCK-B antagonist and should inhibit basal and meal-stimulated gastric acid secretion and enhance gastric emptying of a liquid meal in man. Therefore YF476 might benefit patients with reflux oesophagitis. The compound has been remarkably well tolerated in animal toxicity studies at doses well in excess of the projected therapeutic dose in patients, and merits first administration to healthy volunteers. That study using the oral route of administration is described here. Extrapolation from data obtained with pentagastrin in animals suggest that single doses of less than 1mg of YF476 should be active in man. However, extrapolation from data obtained in comparative studies with the H2-antagonists and with omeprazole in animals suggest that the therapeutic dose in patients with reflux oesophagitis will be larger, in the region of 10mg. A range of single doses will be used in this study. The maximum dose will be 10 times more than the expected therapeutic dose.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: June 1996
• Est. primary completion date: June 1996
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Male and aged 18-45 years.

• No clinically relevant abnormal findings in the clinical history or physical examination at the screening assessment which could interfere with the objectives of the study or make the subject's participation hazardous.

• No clinically relevant abnormal laboratory values at the screening evaluation (Attachment 2).

• A normal ECG at the screening examination.

• A body mass index (Quetelet index) in the range 19-30:

• Body Mass Index = weight [kg]_ height [m]2

• Normal blood pressure and heart rate at the screening examination, i.e. BP 90-150mmHg systolic, 40-95mmHg diastolic; heart rate 40-100 beats/min in seated position.

• Subjects must be of sufficient intelligence to understand the nature of the study and any hazards of their participation in it. They must be able to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire study.

• Subjects must give their written consent to participate after reading the Information-for-Volunteers Leaflet and Consent Form, and after having the opportunity to discuss the study with the Investigator or his deputy.

Exclusion Criteria:

• Clinically relevant abnormal history or physical findings at the screening assessment, which could interfere with the objectives of the study or the safety of the subject's participation.

• Clinically relevant abnormalities of laboratory values or ECG at screening evaluation.

• Presence of acute or chronic illness or history of chronic illness sufficient to invalidate subject's participation in the study or make it unnecessarily hazardous.

• Impaired endocrine, thyroid, hepatic, respiratory or renal function, diabetes mellitus, coronary heart disease or history of any psychotic mental illness.

• Participation in other clinical studies of a new chemical entity or a prescription medicine within the previous 3 months.

• Presence or history of drug or alcohol abuse, or intake of more than 40 units of alcohol weekly.

• Loss of more than 400ml blood during the 3 months before the study, e.g. as a blood donor.

• Use of prescription medication during 30 days before the study.

• Use of an over-the-counter medicine during 7 days before the study

• Blood pressure or heart rate outside those values specified under inclusion criterion (f).

• Possibility that the subject will not cooperate with the requirements of the protocol.

• Evidence of drug abuse on urine testing at study entry.

• Positive test for hepatitis B or C or HIV 1 & 2.

• High risk of hepatitis or HIV infection.

• History of severe allergic disease.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Esophagitis
• Esophagitis, Peptic
• Reflux Oesophagitis

Intervention

Drug:
• YF476
Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows: Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth Groups A & B were dosed alternately, at weekly intervals

Locations

Country	Name	City	State
United Kingdom	Hammersmith Medicines Research	London

Sponsors (2)

Lead Sponsor	Collaborator
Trio Medicines Ltd.	Ferring Pharmaceuticals

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinically relevant changes from baseline in safety assessments	Physical examination, ECG and safety tests of blood and urine at screening and at 24 hours and 7 days after dosing. ECG, blood pressure and heart rate during study period.	6 weeks	Yes
Primary	Numbers of adverse events	Adverse events during study period and at follow-up.	6 weeks	Yes
Primary	Pharmacokinetic parameters: Cmax, Tmax, AUC 0-24 h, T1/2	Blood samples (10 mL) for assay of YF476 at 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours after dosing.; Urine collection: 0-6, 6-12 and 12-24 hours after dosing.	6 weeks	Yes